Suppressive effect of bevacizumab on peritoneal dissemination from gastric cancer in a peritoneal metastasis model

Purpose Vascular endothelial growth factor (VEGF) has been reported to enhance vascular permeability and angiogenesis in the abdominal wall, thereby contributing to peritoneal dissemination with malignant ascites. We conducted this experimental study to find out if bevacizumab, a humanized monoclona...

Full description

Saved in:
Bibliographic Details
Published in:Surgery today (Tokyo, Japan) Japan), 2010-09, Vol.40 (9), p.851-857
Main Authors: Imaizumi, Takuya, Aoyagi, Keishiro, Miyagi, Motoshi, Shirouzu, Kazuo
Format: Article
Language:English
Subjects:
Angiogenesis Inhibitors - administration & dosage
Animals
Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal, Humanized
Ascites - pathology
Bevacizumab
Cell Line, Tumor
Injections, Intraperitoneal
Male
Medicine
Medicine & Public Health
Mice
Mice, Inbred BALB C
Mice, Nude
Mitotic Index
Neoplasm Transplantation
Original Article
Peritoneal Neoplasms - pathology
Peritoneal Neoplasms - prevention & control
Peritoneal Neoplasms - secondary
Stomach Neoplasms - pathology
Surgery
Surgical Oncology
Vascular Endothelial Growth Factor A - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose Vascular endothelial growth factor (VEGF) has been reported to enhance vascular permeability and angiogenesis in the abdominal wall, thereby contributing to peritoneal dissemination with malignant ascites. We conducted this experimental study to find out if bevacizumab, a humanized monoclonal antibody against VEGF, had a suppressive effect on peritoneal dissemination from gastric cancer, in an experimental nude mouse model of peritoneal metastasis. Methods Each mouse was treated with a single intraperitoneal (i.p.) injection of bevacizumab. Five mice were killed, and we measured their body weight, the mean number of tumor nodules, and the volume of ascites. We also extracted retroperitoneal tissues for histological examination, to count the frequency of mitosis, and to calculate the mitotic index. Another five mice were monitored until death, and their mean survival duration was calculated. Results The volume of ascites and the mitotic index were significantly lower in the therapy group than in the nontherapy group ( P = 0.042 and P < 0.01, respectively). The survival curve of the therapy group was significantly higher than that of the nontherapy group ( P = 0.005). Conclusion Bevacizumab may suppress peritoneal dissemination from gastric cancer.
ISSN:0941-1291
1436-2813
DOI:10.1007/s00595-009-4154-y